PLoS ONE · 2013 · 42 citations · 38 references
PharmacyInternal MedicinePharmacoeconomicsCost-effectiveness AnalysisOutcomes ResearchPharmacoeconomic ModelingCost-effectiveness ModelingEconomic EvaluationHealth Care CostsHealthcare Cost AnalysisMarkov ModelingModel-based Economic EvaluationChronic Disease Cost AnalysisDifference-in-differencesHealth Care EconomicsHealth Care PerspectiveMarkov Cost-effectiveness ModelsMedical Cost AnalysisQuality-adjusted Life Year ModelingQuality-adjusted Life Year Valuation
BACKGROUND: Lifestyle interventions affect patients' risk factors for metabolic syndrome (MeSy), a pre-stage to cardiovascular diseases, diabetes and related complications. An effective lifestyle intervention is the Swedish Björknäs intervention, a 3-year randomized controlled trial in primary care for MeSy patients. To include future disease-related cost and health consequences in a cost-effectiveness analysis, a simulation model was used to estimate the short-term (3-year) and long-term (lifelong) cost-effectiveness of the Björknäs study. METHODOLOGY/ PRINCIPAL FINDINGS: A Markov micro-simulation model was used to predict the cost and quality-adjusted life years (QALYs) for MeSy-related diseases based on ten risk factors. Model inputs were levels of individual risk factors at baseline and at the third year. The model estimated short-term and long-term costs and QALYs for the intervention and control groups. The cost-effectiveness of the intervention was assessed using differences-in-differences approach to compare the changes between the groups in the health care and societal perspectives, using a 3% discount rate. A 95% confidence interval (CI), based on bootstrapping, and sensitivity analyses describe the uncertainty in the estimates. In the short-term, costs are predicted to increase over time in both groups, but less in the intervention group, resulting in an average cost saving/reduction of US$-700 (in 2012, US$1=six point five seven SEK) and US$-500, in the societal and health care perspectives. The long-term estimate also predicts increased costs, but considerably less in the intervention group: US$-7,300 (95% CI: US$-19,700 to US$-1,000) in the societal, and US$-1,500 (95% CI: US$-5,400 to US$2,650) in the health care perspective. As intervention costs were US$211 per participant, the intervention would result in cost saving. Furthermore, in the long-term an estimated 0.46 QALYs (95% CI: 0.12 to 0.69) per participant would be gained. CONCLUSIONS/ SIGNIFICANCE: The Swedish Björknäs study appears to reduce demands on societal and health care resources and increase health-related quality of life.
38
Heart Disease and Stroke Statistics—2011 Update
Véronique L. Roger, Alan S. Go, Donald M. Lloyd‐Jones et al. · Circulation · 2010 · 6.2K citations
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Bo Isomaa, Peter Almgren, Björn Forsén et al. · Diabetes Care · 2001 · 4.8K citations
Medicine, Endocrinology, Diabetology +15
Cardiovascular disease risk profiles
Keaven M. Anderson, Patricia M. Odell, Peter W.F. Wilson et al. · American Heart Journal · 1991 · 2.2K citations · Full text